Detection of HBsAg mutants in the blood donor population of Pakistan.

Infection with the Hepatitis B virus (HBV) continues to be one of the leading healthcare issues in Pakistan, affecting over 6 million people. The existence of HBsAg mutants is well documented in many countries. In Pakistan, HBV screening in the majority of the blood banks is performed by Rapid Detec...

Full description

Bibliographic Details
Main Authors: Ahmad Farooq, Usman Waheed, Hasan Abbas Zaheer, Fahad Aldakheel, Shatha Alduraywish, Muhammad Arshad
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5699832?pdf=render
id doaj-ad89d4b69b1e451c8fb19098d18d52f1
record_format Article
spelling doaj-ad89d4b69b1e451c8fb19098d18d52f12020-11-25T01:49:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018806610.1371/journal.pone.0188066Detection of HBsAg mutants in the blood donor population of Pakistan.Ahmad FarooqUsman WaheedHasan Abbas ZaheerFahad AldakheelShatha AlduraywishMuhammad ArshadInfection with the Hepatitis B virus (HBV) continues to be one of the leading healthcare issues in Pakistan, affecting over 6 million people. The existence of HBsAg mutants is well documented in many countries. In Pakistan, HBV screening in the majority of the blood banks is performed by Rapid Detection Devices or ELISA tests. These tests are designed to detect HBsAg, but may not detect the mutant HBsAg. Failure to detect the HBsAg mutant may result in the transmission of HBV infection from donor to recipient. Hence, there is a need to identify a HBsAg assay which can detect mutants in a country where simple and conventional HBsAg assays with varying sensitivity and specificity are used to detect HBV infections.Three routinely used diagnostic tests (Rapid Detection Devices, ELISA and CLIA) for HBsAg were compared with the LIAISON® XL Murex HBsAg Quant Assay to determine the prevalence of HBV mutants in the Pakistani blood donor population. The samples of blood donors from different cities of Pakistan were collected. The testing was performed using SD Bioline rapid assay (n = 1500), ELISA (n = 1500), and Abbott ARCHITECT®CLIA system (n = 1500) at the centers where the donations were collected. All samples (n = 4500) were re-tested for comparative analysis on the LIAISON® XL Murex HBsAg Quant assay (DiaSorin S.p.A.). PCR testing was performed as a gold standard on all discordant samples.119/4500 (2.64%) of the samples were positive for antibodies against HBsAg. The sensitivity of SD Bioline Rapid, GB HBsAg ELISA, Abbott ARCHITECT® and LIAISON® XL Murex HBsAg Quant assay was 17.24%, 43.75%, 90.91%and 100% respectively. The specificity of SD Bioline Rapid, GB HBsAg ELISA, Abbott ARCHITECT® and LIAISON® XL Murex HBsAg Quant Assay was 98.82%, 99.59%, 100% and 100%, respectively.LIAISON® XL Murex HBsAg Quant assay is a highly sensitive, specific and accurate screening assay for detecting wild type as well as mutant HBsAg.http://europepmc.org/articles/PMC5699832?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Ahmad Farooq
Usman Waheed
Hasan Abbas Zaheer
Fahad Aldakheel
Shatha Alduraywish
Muhammad Arshad
spellingShingle Ahmad Farooq
Usman Waheed
Hasan Abbas Zaheer
Fahad Aldakheel
Shatha Alduraywish
Muhammad Arshad
Detection of HBsAg mutants in the blood donor population of Pakistan.
PLoS ONE
author_facet Ahmad Farooq
Usman Waheed
Hasan Abbas Zaheer
Fahad Aldakheel
Shatha Alduraywish
Muhammad Arshad
author_sort Ahmad Farooq
title Detection of HBsAg mutants in the blood donor population of Pakistan.
title_short Detection of HBsAg mutants in the blood donor population of Pakistan.
title_full Detection of HBsAg mutants in the blood donor population of Pakistan.
title_fullStr Detection of HBsAg mutants in the blood donor population of Pakistan.
title_full_unstemmed Detection of HBsAg mutants in the blood donor population of Pakistan.
title_sort detection of hbsag mutants in the blood donor population of pakistan.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description Infection with the Hepatitis B virus (HBV) continues to be one of the leading healthcare issues in Pakistan, affecting over 6 million people. The existence of HBsAg mutants is well documented in many countries. In Pakistan, HBV screening in the majority of the blood banks is performed by Rapid Detection Devices or ELISA tests. These tests are designed to detect HBsAg, but may not detect the mutant HBsAg. Failure to detect the HBsAg mutant may result in the transmission of HBV infection from donor to recipient. Hence, there is a need to identify a HBsAg assay which can detect mutants in a country where simple and conventional HBsAg assays with varying sensitivity and specificity are used to detect HBV infections.Three routinely used diagnostic tests (Rapid Detection Devices, ELISA and CLIA) for HBsAg were compared with the LIAISON® XL Murex HBsAg Quant Assay to determine the prevalence of HBV mutants in the Pakistani blood donor population. The samples of blood donors from different cities of Pakistan were collected. The testing was performed using SD Bioline rapid assay (n = 1500), ELISA (n = 1500), and Abbott ARCHITECT®CLIA system (n = 1500) at the centers where the donations were collected. All samples (n = 4500) were re-tested for comparative analysis on the LIAISON® XL Murex HBsAg Quant assay (DiaSorin S.p.A.). PCR testing was performed as a gold standard on all discordant samples.119/4500 (2.64%) of the samples were positive for antibodies against HBsAg. The sensitivity of SD Bioline Rapid, GB HBsAg ELISA, Abbott ARCHITECT® and LIAISON® XL Murex HBsAg Quant assay was 17.24%, 43.75%, 90.91%and 100% respectively. The specificity of SD Bioline Rapid, GB HBsAg ELISA, Abbott ARCHITECT® and LIAISON® XL Murex HBsAg Quant Assay was 98.82%, 99.59%, 100% and 100%, respectively.LIAISON® XL Murex HBsAg Quant assay is a highly sensitive, specific and accurate screening assay for detecting wild type as well as mutant HBsAg.
url http://europepmc.org/articles/PMC5699832?pdf=render
work_keys_str_mv AT ahmadfarooq detectionofhbsagmutantsintheblooddonorpopulationofpakistan
AT usmanwaheed detectionofhbsagmutantsintheblooddonorpopulationofpakistan
AT hasanabbaszaheer detectionofhbsagmutantsintheblooddonorpopulationofpakistan
AT fahadaldakheel detectionofhbsagmutantsintheblooddonorpopulationofpakistan
AT shathaalduraywish detectionofhbsagmutantsintheblooddonorpopulationofpakistan
AT muhammadarshad detectionofhbsagmutantsintheblooddonorpopulationofpakistan
_version_ 1725004211221954560